Guided Therapeutics to Showcase LuViva® Advanced Cervical Scan at Medica 2012

  Guided Therapeutics to Showcase LuViva® Advanced Cervical Scan at Medica
  2012

 Seeking to add distribution partners to market new women’s health technology

Business Wire

DUSSELDORF, Germany -- November 07, 2012

Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a rapid
and painless testing platform that uses biophotonics for the early detection
of disease, today announced plans to showcase the LuViva® Advanced Cervical
Scan product at the Medica 2012 International Trade Fair taking place November
14-17 in Dusseldorf, Germany.

In anticipation of its international market launch the company plans to meet
with distributors interested in representing LuViva in select markets around
the world. The LuViva booth is located in the USA Pavilion in Hall 16/D18-8 in
the Dusseldorf Trade Fair Centre.

“We are actively seeking to add qualified distributors to our growing LuViva
sales network that have experience introducing innovative technology into the
women’s health market,” said Melissa White, International Sales Manager for
Guided Therapeutics. “LuViva is attracting superior medical device
distributors internationally due to its unique technology and business model
which combines a highly valued device with a single-use disposable. While the
technology allows distributors to differentiate themselves from competitors,
it also provides a viable solution to increasing healthcare quality while
lowering healthcare costs in the countries where they operate. We look forward
to meeting with companies who are interested in being a part of introducing
LuViva to women around the world.”

To schedule appointments, contact Melissa White at +1-770-242-8723, EXT 324,
or e-mail mwhite@guidedinc.com.

LuViva currently has marketing approval from Health Canada and received its
first CE Mark, an ISO 60601 Edition 2 Notification, in July. The company plans
to file an Edition 3 CE Mark application upon completion of product testing,
which is ongoing. Guided Therapeutics was awarded ISO 13485 certification in
January, 2011.

About LuViva^® Advanced Cervical Scan

LuViva is a technologically advanced diagnostic device that scans the cervix
with light and uses spectroscopy to measure how light interacts with the
cervical tissue. Spectroscopy identifies chemical and structural indicators of
precancer that may be below the surface of the cervix or misdiagnosed as
benign. This technique is called biophotonics. Unlike Pap, HPV tests or
biopsies, LuViva does not require laboratory analysis or a tissue sample, and
is designed to provide results immediately, which eliminates costly, painful
and unnecessary testing. LuViva is designed for use with women who have
undergone initial screening and are called back for follow up with a
colposcopy examination, which in many cases, involves taking a biopsy of the
cervix. The device is used in conjunction with the LuViva^® Cervical Guide
single-use patient interface and calibration disposable.

About Medica

Medica is an annual medical trade fair held yearly in Dusseldorf, Germany. It
is represented as the largest medical product trade show in the world with
more than approximately 138,000 visitors and 4,400 exhibitors. For more
information, visit http://www.medica-tradefair.com/

About Guided Therapeutics

Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) is developing a rapid
and painless testing platform for the early detection of disease based on its
patented biophotonic technology that utilizes light to detect disease at the
cellular level. The Company’s first planned product is the LuViva® ^ Advanced
Cervical Scan, a non-invasive device used to detect cervical disease instantly
and at the point of care. In a multi-center clinical trial, with women at risk
for cervical disease, the technology was able to detect cervical cancer up to
two years earlier than conventional modalities, according to published
reports. Guided Therapeutics has also entered into a partnership with Konica
Minolta to develop a non-invasive test for the early detection of esophageal
cancer using the technology platform. For more information, visit:
www.guidedinc.com.

The Guided Therapeutics LuViva^® Advanced Cervical Scan is an investigational
device and is limited by federal law to investigational use. LuViva, the wave
logo and "Early detection, better outcomes" are registered trademarks owned by
Guided Therapeutics, Inc.

Forward-Looking Statements Disclaimer: A number of the matters and subject
areas discussed in this news release that are not historical or current facts
deal with potential future circumstances and developments. The discussion of
such matters and subject areas is qualified by the inherent risks and
uncertainties surrounding future expectations generally and also may
materially differ from Guided Therapeutics’ actual future experience involving
any of or more of such matters and subject areas. Such risks and uncertainties
include those related to the early stage of products in development, the
uncertainty of market acceptance of products, the uncertainty of development
or effectiveness of distribution channels, the intense competition in the
medical device industry, the uncertainty of capital to develop products, the
uncertainty of regulatory approval of products, dependence on licensed
intellectual property, as well as those that are more fully described from
time to time under the heading “Risk Factors” in Guided Therapeutics’ reports
filed with the SEC, including Guided Therapeutics’ Annual Report on Form 10-K
for the fiscal year ended December 31, 2011, and subsequent quarterly reports.

Contact:

Investors:
Cameron Associates
Alison Ziegler, 212-554-5469
or
Guided Therapeutics
Melissa White, 770-242-8723
 
Press spacebar to pause and continue. Press esc to stop.